US/UK/Canada

Share

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Pick a time period -
Tags ( Active)

Meda expands collaboration with the Indian pharmaceutical company Cipla

Meda is broadening its collaboration with the Indian pharmaceutical company Cipla, thereby expanding its exclusive rights to Dymista and future product development. Through the extended partnership, Meda now have full coverage in all growth markets in Latin- and South America, Middle East and Africa and Asia, including more than 120 new markets. Meda and Cipla will cooperate on product development of Dymista. Cipla will be responsible for formulation, while Meda will be responsible for clinical development, registration, marketing and sales. The companies will also collaborate on future

Dymista approved in Europe

Dymista has received medical approval in Europe via the decentralized registration procedure. Dymista is approved for the treatment of seasonal and perennial allergic rhinitis. National registration processes, including negotiations regarding pricing and reimbursement, will now follow in each country prior to launch. Launches are anticipated in 2013 in several countries. "Patients in Europe that suffer from allergic rhinitis will soon have access to a better treatment option than the current standard therapy. The faster and more complete effect offers significant benefit to the growing

Dymista approved by the FDA

The U.S. Food and Drug Administration (FDA) has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis (SAR). In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment. "Allergic rhinitis is an increasing problem. Many patients have severe symptoms that cause inability to work and live a normal life. Dymista can offer an effective treatment for patients suffering from these symptoms”, said Anders Lönner, CEO of Meda AB. “The approval of Dymista represents an important achievement for Meda’s

Positive results for Dymista in three clinical studies

Meda announced today positive results of three studies of MP29-02 (tentatively called Dymista), a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate. The first study demonstrated that continuous treatment with MP29-02 for 1 year was well tolerated in patients with chronic allergic or non-allergic rhinitis, only 2.7% of patients treated with MP29-02 and 2.9% of patients treated with fluticasone propionate discontinued the study due to an adverse event. MP29-02 also provided sustained efficacy over the one-year study period. MP29-02-treated patients

Dymista filed in Europe

The marketing authorization application for Dymista (a novel formulation of azelastine hydrochloride and fluticasone propionate) has been filed in Europe. The application uses a decentralized procedure and the reference member state is Germany. Dymista is a nasal spray formulation for patients with symptomatic treatment of moderate to severe allergic rhinitis and rhinoconjuctivitis. The efficacy and safety of Dymista has been documented in several studies involving over 4,000 patients, including a long-term safety study with more than 600 patients. "The regulatory filing for Dymista

There are no items matching the current filter
There are no more items matching the current filter
Back to top